HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.
Sho WatanabeYasushi GotoHiroyuki YasudaTakashi KohnoNoriko MotoiYuichiro OheHiroyoshi NishikawaSusumu S KobayashiKazuyoshi KuwanoYosuke TogashiPublished in: Thoracic cancer (2021)
EGFR amplification confers resistance to third-generation EGFR-TKIs which can be overcome by HSP90 inhibition. The results provide a preclinical rationale for the use of HSP90 inhibitors to overcome EGFR amplification-mediated resistance.